Canaccord Genuity Initiates Coverage On Tango Therapeutics with Buy Rating, Announces Price Target of $30

Canaccord Genuity analyst John Newman has initiated coverage on Tango Therapeutics (NASDAQ: TNGX) with a Buy rating. The firm has set a price target of $30 for the stock.